WELCOME TO
A fresh approach to Life Science PR & Marketing
Zyme Communications provides PR and marketing services for the life science sector. We support companies to raise their profile, build corporate value and generate interest from commercial leads, investors and partners.
Our
Services
Focused on supporting life science companies to raise their profile, build corporate value, and generate interest, the services we provide include:
PR & Media
- Press releases
- Article writing and placement
- Media interviews
- Messaging
- Copy writing
- Social media
- Media training
- Events
Marketing
- Conference, event and trade show support
- Marketing literature
- Market research
- Campaign development
- Advertising
- Sponsorship
- Product launches
Design & Branding
- Website design and development
- Print collateral development
- Identity and logo creation
- Brand strategy
- Presentation development
- Video production
Investor Relations
- Business plan development
- Presentation development
- PR targeting the life science trade press read by investors
The
Team
An experienced senior team of specialists in life science communications, with expertise gained in-house and agency side, offering the flexibility to support both early-stage companies and large multinationals.
EVENTS
-
Jefferies London Healthcare Conference 2024
-
o2h Influencer Biotech Bootcamp 6.0
-
Genesis 2024
-
J. P. Morgan 2025 Healthcare Conference
CrestOptics and Tomocube partner to advance 3D imaging with new multimodal imaging platform
First commercially available spinning-disk confocal holotomographic instrument, enabling advanced 3D imaging with fluorescence-based detection New system showcased at SPAOM24 (20th-22nd November, Toledo, Spain) Rome, IT, 20 November, 2024: CrestOptics S.p.A., [...]
Tagomics Announces a Multiomic Profiling Co-Marketing Agreement with Agilent
Exclusive program will provide customers with a single, unified workflow for comprehensive genomic profiling and genome-wide epigenetic analysis Cambridge, UK, 20 November 2024: Tagomics Ltd., a pioneering biomarker discovery and [...]
Asimov and RevOpsis Therapeutics Sign Licensing Agreement for High Titer Multispecific-Expressing Cell Line
Strategic agreement will accelerate the manufacturing of fully human multispecific therapies for chronic retinal diseases with high unmet need using Asimov’s CHO Edge System Boston, Massachusetts, and San Carlos, California, [...]